SynthesisFrontiers in pharmacology2025
The preventive effect of sodium-glucose co-transporter-2 inhibitors on atrial fibrillation and atrial flutter in patients with chronic kidney disease: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Periodontal Inflammation to Atrial Fibrillation: Molecular Links Through Thrombospondin-1, Galectin-3, and SGLT2-Related Pathways.International journal of molecular sciences · 2026Review
- LAAEV-centric atrial failure phenotype and a novel integrative score for predicting early recurrence after AF ablation.Frontiers in cardiovascular medicine · 2026Article
- The preventive effect of sodium-glucose co-transporter-2 inhibitors on life-threatening arrhythmias in patients with chronic kidney disease: a meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Impact of intracardiac echocardiography on radiofrequency catheter ablation for atrial fibrillation: a clinical study on procedural parameters and post-procedural recurrence.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The presence of atrial fibrillation (AF) and atrial flutter (AFL) in patients with chronic kidney disease (CKD) can exacerbate renal dysfunction, which in turn increases the onset of AF or AFL. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been proven to have cardiac and renal protective effects. The meta-analysis was performed to investigate whether SGLT2i can reduce the risk of AF/AFL in patients with CKD. Methods: PubMed, Embase, Cochrane Library, and Clinical Trials.gov were searched up to December 2024. Randomized controlled trials (RCTs) comparing of SGLT2i and placebo on AF/AFL in patients with CKD were included. Risk ratio (RR) with 95% confidence interval (CI) were calculated in the overall population and selected subgroups. Results: 10 RCTs involving 28,712 patients were included. SGLT2i significantly reduced the risk of the composite events of AF and AFL in patients with CKD (0.65% vs. 0.91%; RR 0.73, 95% CI 0.56-0.95, Conclusion: SGLT2i could reduce the risk of the composite events of AF and AFL in patients with CKD, and also could reduce the risk of AF in trials with large sample size and long follow-up duration. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251053244.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.